Crossover Design on the Bioequivalence of Pharmaceuticals - A Case of Study

被引:0
|
作者
Teodoro, M. Filomena [1 ,2 ]
Andrade, Marina A. P. [3 ,4 ]
Oliveira, Teresa A. [5 ,6 ]
机构
[1] Naval Acad, Ctr Naval Res, CINAV, Portuguese Navy, P-2810001 Almada, Portugal
[2] Lisbon Univ, Ctr Computat & Stochast Math, Inst Super Tecn, CEMAT, P-1048001 Lisbon, Portugal
[3] Inst Univ Lisboa, ISCTE, P-1649026 Lisbon, Portugal
[4] Univ Lisbon, ISTAR, P-1649026 Lisbon, Portugal
[5] Univ Aberta, Dept Ciencias & Tecnol, P-1269001 Lisbon, Portugal
[6] Univ Lisbon, Fac Ciencias, CEAUL, P-1649014 Lisbon, Portugal
关键词
experimental design; clinical trials; analysis of variance; bio-equivalence; computational methods; CLINICAL-TRIALS; RANDOMIZATION; ALLOCATION;
D O I
10.1007/978-3-031-65223-3_15
中图分类号
TP18 [人工智能理论];
学科分类号
081104 ; 0812 ; 0835 ; 1405 ;
摘要
This study performs experimental design and analysis of variance in assessing the bioequivalence of two treatments, which involves evaluating the efficacy of different treatments administered to two distinct cohorts of patients: the control group and the test group. In order to compare the control group that received the reference medication, with the test/treatment group that received the investigational drug, a crossover experimental design was employed. The respective analysis of variance was conducted, taking into consideration both intra-subject and inter-subject variability in formulating the probabilistic model. This included specifying tests to detect carryover effects and period effects. The practical implementation of the proposed model involved validating the hypothesis, revealing that the carry-over effect was found to be not significant, when assessed at the usual levels of significance (1% and 5%). In terms of the treatments, it was concluded that there was statistical significance, leading to the assertion that the studied pharmaceuticals were not bioequivalent.
引用
收藏
页码:219 / 234
页数:16
相关论文
共 50 条
  • [21] Comparative study on the bioequivalence of two formulations of pravastatin - Data from a crossover, randomised, open-label bioequivalence study in healthy volunteers
    Almeida, S
    Filipe, A
    Almeida, A
    Gich, I
    Antonijoan, R
    Puntes, M
    Barbanoj, M
    Caturla, MC
    [J]. ARZNEIMITTELFORSCHUNG-DRUG RESEARCH, 2006, 56 (02): : 70 - 75
  • [22] BIOAVAILABILITY BIOEQUIVALENCE - STUDY DESIGN AND STATISTICAL ISSUES
    METZLER, CM
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 29 (04): : 289 - 292
  • [23] Comparative crossover, randomized, open-label bioequivalence study on the bioequivalence of two formulations of thioctic acid in healthy volunteers
    Mignini, Fiorenzo
    Streccioni, Valentino
    Tomassoni, Daniele
    Traini, Enea
    Amenta, Francesco
    [J]. CLINICAL AND EXPERIMENTAL HYPERTENSION, 2007, 29 (08) : 575 - 586
  • [24] A crossover study to evaluate the pharmacokinetics and bioequivalence of hydroxychloroquine tablets in healthy Chinese subjects
    Feng, Jie
    Kuang, Shuang-yu
    Wan, Jun-han
    Li, Rong
    Zhu, Yi-jie
    Cai, Bei-lei
    Guan, Lei
    Zhang, Zheng
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2024, 62 (06) : 284 - 292
  • [25] Three-ways crossover bioequivalence study of cephalexin in healthy Malay volunteers
    Liew, Kai Bin
    Peh, Kok Khiang
    Loh, Gabriel Onn Kit
    Tan, Yvonne Tze Fung
    [J]. DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2014, 40 (09) : 1156 - 1162
  • [26] Exchangeability in the case-crossover design
    Mittleman, Murray A.
    Mostofsky, Elizabeth
    [J]. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2014, 43 (05) : 1645 - 1655
  • [27] Bioequivalence studies of reformulated pharmaceuticals newly off patent
    不详
    [J]. ASIAN BIOMEDICINE, 2014, 8 (02) : 137 - 138
  • [28] The Nonclinical Fertility Study Design for Pharmaceuticals
    Lerman, Steven A.
    Hew, Kok Wah
    Stewart, Jane
    Stump, Donald G.
    Wise, L. David
    [J]. BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY, 2009, 86 (06) : 429 - 436
  • [29] Generic pharmaceuticals, regulatory aspects, bioequivalence investigation, and perception
    Bhushan, Ravi
    Martens, Jurgen
    [J]. EXPERT OPINION ON DRUG SAFETY, 2024, 23 (02) : 177 - 186
  • [30] Average bioequivalence for two-sequence two-period crossover design with incomplete data
    Lee, JY
    Kim, BC
    Park, SG
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2005, 15 (05) : 857 - 867